Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome.

Scambi C, Ugolini S, Tonello M, Bortolami O, De Franceschi L, Castagna A, Lotti V, Corbella M, Raffaelli R, Caramaschi P, Mattia E, Biasi D, Ruffatti A.

Am J Reprod Immunol. 2019 Dec;82(6):e13185. doi: 10.1111/aji.13185. Epub 2019 Sep 16.

PMID:
31479579
2.

Protective role of the dynamin inhibitor Dynasore against the cholesterol-dependent cytolysin of Trueperella pyogenes.

Preta G, Lotti V, Cronin JG, Sheldon IM.

FASEB J. 2015 Apr;29(4):1516-28. doi: 10.1096/fj.14-265207. Epub 2014 Dec 30.

3.

Immunohistochemical analysis of dendritic cells in skin lesions: correlations with survival time.

Bacci S, Defraia B, Cinci L, Calosi L, Guasti D, Pieri L, Lotti V, Bonelli A, Romagnoli P.

Forensic Sci Int. 2014 Nov;244:179-85. doi: 10.1016/j.forsciint.2014.08.024. Epub 2014 Sep 2.

PMID:
25259940
4.

Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts.

Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, Lotti V, Compasso S, Bogni S, Lombardi L, Maiolo AT, Neri A.

Cancer Res. 2000 Aug 1;60(15):4058-61.

5.

In vitro pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors.

Chang RS, Lotti VJ, Chen TB, O'Malley SS, Bendesky RJ, Kling PJ, Kivlighn SD, Siegl PK, Ondeyka D, Greenlee WJ, et al.

Eur J Pharmacol. 1995 Dec 29;294(2-3):429-37.

PMID:
8750703
6.

Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.

Chang LL, Ashton WT, Flanagan KL, Chen TB, O'Malley SS, Zingaro GJ, Kivlighn SD, Siegl PK, Lotti VJ, Chang RS, et al.

J Med Chem. 1995 Sep 15;38(19):3741-58.

PMID:
7562905
7.

Discovery of L-162,313: a nonpeptide that mimics the biological actions of angiotensin II.

Kivlighn SD, Huckle WR, Zingaro GJ, Rivero RA, Lotti VJ, Chang RS, Schorn TW, Kevin N, Johnson RG Jr, Greenlee WJ, et al.

Am J Physiol. 1995 Mar;268(3 Pt 2):R820-3.

PMID:
7900925
8.

Triazolinone biphenylsulfonamides as angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypes.

Chang LL, Ashton WT, Flanagan KL, Chen TB, O'Malley SS, Zingaro GJ, Siegl PK, Kivlighn SD, Lotti VJ, Chang RS, et al.

J Med Chem. 1994 Dec 23;37(26):4464-78.

PMID:
7799397
9.

A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.

Chakravarty PK, Naylor EM, Chen A, Chang RS, Chen TB, Faust KA, Lotti VJ, Kivlighn SD, Gable RA, Zingaro GJ, et al.

J Med Chem. 1994 Nov 25;37(24):4068-72. No abstract available.

PMID:
7990105
10.

Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.

Dhanoa DS, Bagley SW, Chang RS, Lotti VJ, Chen TB, Kivlighn SD, Zingaro GJ, Siegl PK, Patchett AA, Greenlee WJ.

J Med Chem. 1993 Dec 24;36(26):4239-49. Erratum in: J Med Chem 1994 Apr 1;37(7):1034.

PMID:
8277506
11.

Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.

Dhanoa DS, Bagley SW, Chang RS, Lotti VJ, Chen TB, Kivlighn SD, Zingaro GJ, Siegl PK, Patchett AA, Greenlee WJ.

J Med Chem. 1993 Dec 24;36(26):4230-8.

PMID:
8277505
12.

(Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.

Dhanoa DS, Bagley SW, Chang RS, Lotti VJ, Chen TB, Kivlighn SD, Zingaro GJ, Siegl PK, Chakravarty PK, Patchett AA, et al.

J Med Chem. 1993 Nov 12;36(23):3738-42. No abstract available.

PMID:
8246245
13.

Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.

Ashton WT, Hutchins SM, Greenlee WJ, Doss GA, Chang RS, Lotti VJ, Faust KA, Chen TB, Zingaro GJ, Kivlighn SD, et al.

J Med Chem. 1993 Nov 12;36(23):3595-605.

PMID:
8246227
14.

A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor.

de Laszlo SE, Quagliato CS, Greenlee WJ, Patchett AA, Chang RS, Lotti VJ, Chen TB, Scheck SA, Faust KA, Kivlighn SS, et al.

J Med Chem. 1993 Oct 15;36(21):3207-10. No abstract available.

PMID:
8230109
15.

Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.

Chang LL, Ashton WT, Flanagan KL, Strelitz RA, MacCoss M, Greenlee WJ, Chang RS, Lotti VJ, Faust KA, Chen TB, et al.

J Med Chem. 1993 Aug 20;36(17):2558-68.

PMID:
8355255
16.

Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.

Ashton WT, Cantone CL, Chang LL, Hutchins SM, Strelitz RA, MacCoss M, Chang RS, Lotti VJ, Faust KA, Chen TB, et al.

J Med Chem. 1993 Mar 5;36(5):591-609.

PMID:
8496939
18.

AT1 receptors mediate the release of prostaglandins in porcine smooth muscle cells and rat astrocytes.

Leung KH, Chang RS, Lotti VJ, Roscoe WA, Smith RD, Timmermans PB, Chiu AT.

Am J Hypertens. 1992 Sep;5(9):648-56.

PMID:
1418854
19.

In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.

Siegl PK, Chang RS, Mantlo NB, Chakravarty PK, Ondeyka DL, Greenlee WJ, Patchett AA, Sweet CS, Lotti VJ.

J Pharmacol Exp Ther. 1992 Jul;262(1):139-44.

PMID:
1625193
20.

In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist.

Chang RS, Siegl PK, Clineschmidt BV, Mantlo NB, Chakravarty PK, Greenlee WJ, Patchett AA, Lotti VJ.

J Pharmacol Exp Ther. 1992 Jul;262(1):133-8.

PMID:
1625192
21.

Cardiac angiotensin receptors: effects of selective angiotensin II receptor antagonists, DUP 753 and PD 121981, in rabbit heart.

Scott AL, Chang RS, Lotti VJ, Siegl PK.

J Pharmacol Exp Ther. 1992 Jun;261(3):931-5.

PMID:
1602398
22.

Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.

Mantlo NB, Chakravarty PK, Ondeyka DL, Siegl PK, Chang RS, Lotti VJ, Faust KA, Chen TB, Schorn TW, Sweet CS, et al.

J Med Chem. 1991 Sep;34(9):2919-22. No abstract available.

PMID:
1895308
23.
24.

Two angiotensin II binding sites in rat brain revealed using [125I]Sar1, Ile8-angiotensin II and selective nonpeptide antagonists.

Chang RS, Lotti VJ, Chen TB, Faust KA.

Biochem Biophys Res Commun. 1990 Sep 14;171(2):813-7.

PMID:
2403363
25.
26.

Novel glutamic acid derived cholecystokinin receptor ligands.

Freidinger RM, Whitter WL, Gould NP, Holloway MK, Chang RS, Lotti VJ.

J Med Chem. 1990 Feb;33(2):591-5.

PMID:
2299627
28.

Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.

Bock MG, DiPardo RM, Evans BE, Rittle KE, Whitter WL, Veber DF, Freidinger RM, Chang RS, Chen TB, Lotti VJ.

J Med Chem. 1990 Jan;33(1):450-5. Erratum in: J Med Chem 1990 Sep;33(9):2679.

PMID:
2153212
29.

Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted benzolactams.

Parsons WH, Patchett AA, Holloway MK, Smith GM, Davidson JL, Lotti VJ, Chang RS.

J Med Chem. 1989 Aug;32(8):1681-5.

PMID:
2754692
30.

Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.

Chang RS, Chen TB, Bock MG, Freidinger RM, Chen R, Rosegay A, Lotti VJ.

Mol Pharmacol. 1989 Jun;35(6):803-8.

PMID:
2733696
31.
32.

Novel cholecystokinin antagonists from Aspergillus alliaceus. I. Fermentation, isolation, and biological properties.

Goetz MA, Monaghan RL, Chang RS, Ondeyka J, Chen TB, Lotti VJ.

J Antibiot (Tokyo). 1988 Jul;41(7):875-7.

33.

A peripherally acting alpha-2 adrenoceptor antagonist: L-659,066.

Clineschmidt BV, Pettibone DJ, Lotti VJ, Hucker HB, Sweeney BM, Reiss DR, Lis EV, Huff JR, Vacca J.

J Pharmacol Exp Ther. 1988 Apr;245(1):32-40.

PMID:
2896239
35.

Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines.

Bock MG, DiPardo RM, Evans BE, Rittle KE, Freidinger RM, Chang RS, Lotti VJ.

J Med Chem. 1988 Jan;31(1):264-8. No abstract available.

PMID:
3336026
36.

Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.

Bock MG, DiPardo RM, Evans BE, Rittle KE, Veber DF, Freidinger RM, Chang RS, Lotti VJ.

J Med Chem. 1988 Jan;31(1):176-81.

PMID:
3336017
37.

Fasting and L-364,718 prevent cholecystokinin-induced elevations of plasma insulin levels.

Reagan JE, Robinson JL, Lotti VJ, Goldman ME.

Eur J Pharmacol. 1987 Dec 1;144(2):241-3.

PMID:
3325297
38.

Pharmacological profile of a new potent and specific alpha 2-adrenoceptor antagonist, L-657,743.

Pettibone DJ, Clineschmidt BV, Lotti VJ, Baldwin JJ, Huff JR, Randall WC, Vacca J, Young SD.

Naunyn Schmiedebergs Arch Pharmacol. 1987 Aug;336(2):169-75.

PMID:
2891039
39.

Characterization of [3H](+/-)L-364,718 binding to solubilized cholecystokinin (CCK) receptors of rat pancreas.

Chang RS, Lotti VJ, Chen TB.

Biochem Pharmacol. 1987 May 15;36(10):1709-14.

PMID:
3593394
40.

[An intra-oral device for orojejunal feeding of low-weight neonates].

Marani M, Biasini G, Miano A, Casadei G, Montaguti A, Lotti V, Biasini A, Montaguti L, Righi F, Tombetti F.

Pediatr Med Chir. 1987 May-Jun;9(3):301-2. Italian.

PMID:
3118340
41.

In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist.

Lotti VJ, Pendleton RG, Gould RJ, Hanson HM, Chang RS, Clineschmidt BV.

J Pharmacol Exp Ther. 1987 Apr;241(1):103-9.

PMID:
2437282
42.

Tifluadom, a kappa-opiate agonist, acts as a peripheral cholecystokinin receptor antagonist.

Chang RS, Lotti VJ, Chen TB, Keegan ME.

Neurosci Lett. 1986 Dec 12;72(2):211-4.

PMID:
3027627
44.

Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility.

Bock MG, DiPardo RM, Rittle KE, Evans BE, Freidinger RM, Veber DF, Chang RS, Chen TB, Keegan ME, Lotti VJ.

J Med Chem. 1986 Oct;29(10):1941-5.

PMID:
3761313
46.
48.

L-654,284 a new potent and selective alpha 2-adrenoceptor antagonist.

Pettibone DJ, Clineschmidt BV, Lotti VJ, Martin GE, Huff JR, Randall WC, Vacca J, Baldwin JJ.

Naunyn Schmiedebergs Arch Pharmacol. 1986 Jun;333(2):110-6.

PMID:
2875395
49.

Thyrotropin-releasing hormone receptors in gut tissues resemble pituitary receptors.

Lotti VJ, Chang RS, Cerino DJ, Kling PJ, Veber DF, Nutt RF.

Neurosci Lett. 1986 Feb 28;64(2):173-6.

PMID:
3008042
50.

Characterization of [3H]pentagastrin binding in guinea pig gastric glands--an alternative convenient ligand for receptor binding assay.

Chang RS, Lotti VJ, Keegan ME, Kunkel KA.

Biochem Biophys Res Commun. 1986 Jan 29;134(2):895-9.

PMID:
3004471

Supplemental Content

Support Center